Printer Friendly

U.S. ALCOHOL TESTING SUBMITS NEW 510(k) APPLICATION TO FDA

 RANCHO CUCAMONGA, Calif., May 7 /PRNewswire/ -- Gary S. Wolff, chief financial officer, announced today that U.S. Drug Testing Inc. (USDT), a wholly owned subsidiary of U.S. Alcohol Testing of America Inc. (USAT) (AMEX: AAA), has submitted application to the FDA for its assay that detects opiates, including heroin and morphine utilizing the Flow Immunosensor technology.
 The company believes that its recently completed performance evaluation studies of the opiate assay involving urine substantiate the claims made in its FDA filing, which proves equivalency to already approved devices.
 On May 3, 1993, the company received marketing approval from the FDA for its 510(k) application submitted on Feb. 22, 1993, for the assay which detects cocaine and its metabolite benzoylecogine. The company will begin marketing after it has proven equivalency of the further assays including the now-submitted opiates assay. Submissions of the remaining assays -- marijuana, amphetamines and PCP -- are expected over the next several months.
 The Flow Immunosensor technology provides a more sensitive method for testing for drugs of abuse while significantly decreasing the assay time and cost. This technology, developed by scientists at the Naval Research laboratory, was licensed to the company in January 1992, from the United States government through the Technology Transfer Act. A subsequent one-year Cooperative Research and Development Agreement was signed in April 1992, and has been extended for an additional six months.
 U.S. Alcohol Testing of America Inc. manufactures evidential and screening equipment for alcohol breath testing analysis used by law enforcement agencies and industry.
 -0- 5/7/93
 /CONTACT: Gary S. Wolff, CFO of U.S. Alcohol Testing of America, 909-466-8378/
 (AAA)


CO: U.S. Drug Testing Inc.; U.S. Alcohol Testing of America Inc. ST: California IN: HEA SU:

JB-BP -- LA008 -- 5788 05/07/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 7, 1993
Words:297
Previous Article:CHALLENGE FOR NEW UFW PRESIDENT
Next Article:AMERICAN EXPRESS LAUNCHES SENIOR MEMBERSHIP
Topics:


Related Articles
DRUG SCREENING SYSTEMS' PCP TEST CLEARED FOR MARKETING BY THE FDA
U.S. DRUG TESTING RECEIVES FDA MARKETING APPROVAL
COMPANY SUBMITS 510(k) APPLICATION TO FDA FOR PHENCYCLIDINE ASSAY
BIO-VASCULAR FILES FOR FDA CLEARANCE TO MARKET VASCU-GUARD PRODUCT FOR PERIPHERAL VASCULAR SURGERY
BIOPOOL RECEIVES APPROVAL TO MARKET CALIBRATOR FOR USE WITH U.S. DRUG TESTING INC. SYSTEM
EDITEK RECEIVES SECOND VERDICT FDA PRE-MARKET CLEARANCE
THERMOLASE FILES 510(K) APPLICATION WITH FDA
FIDUS MEDICAL TECHNOLOGY CORPORATION ANNOUNCES THE SUBMISSION OF THE INVESTIGATIONAL DEVICE EXEMPTION (IDE) TO FDA FOR REVIEW
Possis Medical Inc. Moves Toward U.S. Marketing Clearance For AngioJet
Immucor Receives Second Round of FDA Questions on ABS2000

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters